We designed the N-methylanthranilic-desferrioxamine (MA-DFO) as a fluorescent iron(III) chelator with improved membrane permeation properties. Upon binding of iron(III), MA-DFO fluorescence is quenched, thus allowing traceability of drug-iron(III) interactions. MA-DFO is well tolerated by mammalian cells in culture. Its antimalarial activity is pronounced: IC50 values on in vitro (24-h) growth of Plasmodium fakciparum were 3±1 MM for MA-DFO compared with 30±8 for DFO. The onset of growth inhibition of rings or trophozoites occurs 2-4 h after exposure to 13 gM MA-DFO. This effect is commensurate with MA-DFO permeation into infected cells. In a 24-h exposure to MA-DFO or DFO, trophozoites take up either compound to -10% of the external concentration, rings to 5%, and noninfected cells to < 1%. Red cells encapsulated with millimolar concentrations of DFO or MA-DFO fully support parasite invasion and growth. We conclude that extracellular MA-DFO and DFO gain selective access into parasites by bypassing the host. The rate-limiting step is permeation through the parasite membrane, which MA-DVO accomplishes faster than DFO, in accordance with its iigher hydrophobicity. These views are consistent with the proposed duct, which apparently provides parasitized cells with a window to the external medium. (J. Clin. Invest. 1993. 91:218-224.) 
Recently it was shown that DFO congeners display effective antimalarial activity both in vitro (2) (3) (4) (5) and in vivo (4, (6) (7) (8) (9) , but as with many other drugs, their mode of action has remained elusive (1) . The information available indicates that DFO acts without affecting serum (4, 10) or normal red cell iron pools (3, 10) , that it gains a restricted access to infected cells ( 11 ), and that its antimalarial action is manifested only in the advanced stages of parasite development and only after prolonged exposure of cells to drug (3, 12) . All this evidence implies that DFO gains a slow and limited access to the mature stages of erythrocytic parasites where it exerts cytotoxic action on still unidentified parasite targets. Interestingly, unlike its cytostatic effect on various mammalian cells in culture (13) (14) (15) , the antimalarial effect of DFO in vitro might be similar to those of highly permeant reversed siderophores (RSFs) (10) , which cause irreversible inhibition of parasite growth ( 10) . The most hydrophobic members ofthis genre, when compared with DFO as antimalarials, displayed demonstrably faster (five-O0-fold) action, 10-fold lower IC50, multistage activity, and no damage to mammalian cells in culture ( 10, 15) .
In general, the antimalarial action of iron chelators, which act by scavenging intracellular iron, is dictated by the speed with which the agents reach the relevant intracellular pools and extract iron from critical sources ( 1) . Selective accessibility to parasitized versus nonparasitized cells can be accomplished by drug design provided the permeation routes to parasites are identified and characterized ( 16, 17) . In an attempt to understand the mode of action of DFO as an antimalarial agent, we have assessed in this work the pathways by which DFO accesses the erythrocytic parasites. To accomplish the present goal we tagged DFO at its NH2 terminus with the fluorescent N-methylanthranilate (MA) and obtained MA-DFO (Figure 1 ). This derivatization was expected to be conservative of the ironbinding capacity and metal selectivity ofDFO, while imparting both higher hydrophobic character for improved permeation and fluorescent properties for tracing of the drugs. The results ofthis study indicate that neither DFO nor MA-DFO permeate to any significant level into normal red cells or egress from red cell containers (RCCs) (which retain > 80% of their hemoglobin after resealing) loaded with drug by encapsulation. RCCs are invaded by parasites equally well as normal cells and demonstrably support parasite growth irrespective of whether they contain millimolar concentrations ofdrugs. The data pre- sented indicate that neither DFO nor MA-DFO can approach the parasites from within the erythrocytes. Although both agents gain direct access to the erythrocytic parasite by bypassing the host cell cytosol (i.e., directly from the medium), MA-DFO apparently crosses the parasite plasma membrane faster than DFO and therefore it displays improved antimalarial activity. This idea is consistent with the recently proposed aqueous duct, which allows direct access of medium components to the parasite external surface ( 18 hematocrit. The growth medium was replaced daily and the cultures were gassed with a mixture of 90% N2, 5% C02, and 5% 02 (19, 20) . Cells were usually harvested or subcultured when the parasitemia reached 15-20%, as determined microscopically by thin blood smears stained with Giemsa. Trophozoite and early schizont stages were routinely isolated by the gelatin flotation method (21) or the Percoll-alanine method as described elsewhere (20, 22 Effect on parasite growth. Upon reaching the trophozoite stage (10-20% parasitemia), the cells were washed with growth medium, resuspended to 2% hematocrit and 1-2% parasitemia, and distributed into wells of a 24-well microtiter plate (0.6 ml per well). Inhibitors were added at the indicated concentrations in duplicate wells, the plate was transferred to a candle jar and incubated at 37°C for the indicated periods oftime (2-24 h). After the indicated period, the supernate was removed, the cells were washed with fresh growth medium and returned to culture conditions (with or without inhibitor), so as to complete a 24-h incubation period. Samples were withdrawn for microscopic examination of newly formed rings or trophozoites, as applicable, and [3H]hypoxanthine was added to final activity of 5 gCi/ml.
After an additional 24-h incubation period, cells were transferred in triplicate samples to 96-well plate and harvested in a cell harvester (Dynatech Laboratories, Inc., Chantily, VA). The filters were washed with distilled water, dried for 2 h at 60°C, and transferred into toluenebased scintillation fluid for counting of radioactivity. Control samples of noninfected and infected cells exposed to DMSO alone at the same final concentrations in the different systems were subjected to the same treatments as those described above. The number ofequivalent experiments carried out on different blood samples was three to five.
Drug action. Stage and time dependence of drug action were assessed by exposing either ring or trophozoite cultures ( 1-2% parasitemia, 2% hematocrit) to the drug for 1 to 18 h while following [3H]-hypoxanthine incorporation into nucleic acids. In some cases RCC-encapsulated drug or lysates derived from them were added to parasite cultures and assessed for [3H ] hypoxanthine incorporation.
The IC50 values of drugs on parasite growth were calculated from the profiles of parasite growth using the Dixon method ( 15) as published elsewhere ( 10) .
Permeation properties offree ligands and iron complexes in normal and infected red cells. Ingress ofDFO and ofMA-DFO into normal and infected cells (10% hematocrit, > 80% parasitemia) was measured either with free drug (MA-DFO) or after complexation of DFO or MA-DFO (at 40 ,M) with 4 ,uM unlabeled iron(III)CI3 and 59Fe citrate (5 x 105 cpm/ ml) in RPMI. After various times of incubation at 37°C (0-24 h), cells were thoroughly washed with isotonic NaCl containing 10 mM EDTA, pH 7.4, and lysed with distilled water. 59Fe was counted in scintillation fluid (Beckman Instruments Inc.) and fluorescent MA-DFO was determined after perchloric acid precipitation in the presence ofEDTA followed by neutralization with KOH and alkalinization with Tris-Base, as described above. The number of cells was obtained from the hemoglobin absorption at 540 nm (20) . Egress experiments on RCCs were carried out after encapsulation ofnormal cells with drugs (4 mM DFO and 1.3 mM MA-DFO) and after the efflux at 37°C into RPMI lacking indicator (2% hematocrit). Total egressed material and extracellular hemoglobin were determined at different times.
Results
It is known that NH2-terminal derivatization of DFO with nitrobenzyl-diazole (NBD) does not reduce the iron(III)-bind-ing capacity of the drug ( 1 5 ). With the aim of obtaining a fluorescent and generally nontoxic DFO derivative (the NBD group conferred DFO with toxic properties to some cells in culture; our unpublished observations) we opted for the conjugation ofthe N-methylanthranilic acid group, resulting in MA-DFO (Fig. 1) . MA conferred DFO with fluorescent properties, relatively higher hydrophobicity (i.e., partition coefficient), and traceability, which was manifested as iron(III)-mediated quenching of fluorescence upon formation of the MA-DFOiron(III) complex (Fig. 2) 
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The apparent IC50 (Fig. 6) . The level ofadsorption was almost invariant with drug concentration attained inside the RCCs: 10% for MA-DFO (intracellular, 1.3 mM) and < 3% for DFO (intracellular, 4 mM). The adsorbed MA-DFO completely desorbed or leaked out from the RCCs in < 2 h at 37°C, after which no release of drug was observed over a 24- (Fig. 7) . A direct proof for invasion into RCCs containing DFO or MA-DFO (millimolar levels) was obtained by labeling the drug containing RCCs with traces of drug-59Fe complexes (at micromolar levels). 24 h after addition of trophozoites to RCCs, the newly formed rings were segregated from noninfected cells by the Percoll-sorbitol method and the 59Fe/hemoglobin ratio was compared with drug-free RCCs (Fig. 7,  bottom) . As seen, very similar values were obtained for all types of RCCs, indicating similar invasion into cells irrespective of whether they contained the drug. The inhibitory effect of material released from RCCs was precisely the same as that observed with free drug added to cells. This proves not only that the drugs were indeed encapsulated but also that they were (at least initially) available for biological action should they become accessible to the relevant parasite compartments. To directly demonstrate that parasites not only invaded but also developed inside drug-containing RCCs, we followed their growth in terms of nucleic acid synthesis (Fig. 8) . At millimolar concentrations, encapsulated drugs did not interfere with the intraerythrocytic development of parasites whereas drug added extracellularly was inhibitory even at 100-fold lower concentrations. Any inhibitory effect found with encapsulated drug, particularly MA-DFO, could be fully explained by the presence of drug in the outer medium, as exogenously supplemented iron(III) abrogated those effects. That drug derived most probably from RCCs by leakage or desorption, as shown previously in Fig. 6 . Moreover, if RCCs loaded with drugs were washed and used as targets for parasite invasion and growth after drug leak ceased (2 h incubation at 37°C; Fig. 6 ), no inhibitory effect of encapsulated MA-DFO was obtained (not shown). Finally, a direct proof that encapsulated MA-DFO and DFO were not neutralized by red cell cytosol components was obtained by testing the RCC lysates on parasite growth. As shown in Fig. 8 , the inhibitory capacity of these drugs was largely retained in the drug-containing RCCs whereas shamloaded RCC lysates had virtually no effect at equivalent dilutions ( 1:100 of original lysates). The fact that inhibition was completely eliminated by addition of exogenous iron(III) to RCC lysates indicated that the active component of the lysates had iron (I11)-binding capacity.
Discussion
The study of the mode of action of antimalarial agents is important for the design of novel therapeutic tools, which are in urgent demand (23) . This truism also applies to iron chelators, which have already scored success in the management of various diseases ( 1 ) , including malaria (9) . To gain knowledge on the mode of action of iron chelators as antimalarial agents and to determine the basis for their specific effects on infected cells it is necessary to delineate the routes by which they permeate into cells and to identify the critical iron pools. Our limited understanding reflects in part the lack of reliable probes for detection of the drugs, and in the case of malaria, for tracing their fate in a highly compartmentalized cell such as the P. falciparum-infected cell. We have recently undertaken the initiative to design fluorescent derivatives of iron chelators by The novel MA-DFO showed improved antimalarial performance when compared with DFO as manifested by its 10-fold lower IC50, faster speed of action, and activity on both early and mature stages of parasite growth. We attributed these improvements to the higher partition coefficient conferred by the MA group, which in turn increased its permeation into infected cells. Moreover, the structural changes in DFO did not significantly alter the permselectivity of infected and noninfected cells for the derivatized DFO. Although the differential performance of MA-DFO and DFO was manifested in the speed of action of these drugs on trophozoites, the same could not be unequivocally said about the effects on rings shown in Fig. 3 . The possibility that a minor undetectable fraction of early trophozoites or late rings might have been present in the predominantly ring culture could not be dismissed. Due to the relatively higher metabolic capacity oftrophozoites compared with rings, incorporation of label into nucleic acid might have been dominated by the contaminant population. However, the fact that in rings the onset of drug inhibitory activity was > 2-4 h later than in trophozoites served as an indication that the observed effects were obtained on genuine rings rather than on contaminating trophozoites.
One of the salient features of DFO and MA-DFO uptake into infected cells is that even after hours of incubation with drug only 15% of the external concentration is attained within the infected cell (assuming the entire cell volume as drug available space). Similar results were previously reported in a study involving '4C-DFO (11), which demonstrated a threefold higher permeation into infected compared with noninfected cells. The apparent restricted permeation of DFO and MA-DFO into infected cells raises the question of which compartment(s) are accessed by DFO and MA-DFO and which are the relevant membranes they need to cross to reach those compartments. The accepted view depicts the parasite enclosed in the red cell and bound by a parasitophorus vacuole membrane (Fig. 9) . To gain access into parasite, drugs would need to cross several membranes and diffuse through various aqueous compartments. Previous biophysical analysis led to a complex picture with multiple and distinct pathways ofentry into the parasitized erythrocyte and the enclosed parasite ( 16, 17) . A recent study proposed a novel pathway ofaccess ofsubstances into the parasite via an aqueous duct leading to parasite outer membrane ( 18) . The validity of that pathway has been questioned (25) but firmly defended (26) . Clearly exogenous agents can gain access to the parasitized cell as a whole by alternative or parallel routes that might lead to different intracellular compartments or even to the same compartments by a combination of parallel and serial routes. From within the host cell cytosol, the agents can gain access to the parasite compartments only by sequential crossing ofthe parasitophorous vacuole membrane (or duct membrane), diffusion in the intermembranous space, and crossing the parasite plasma membrane (Fig. 9 ). Small and lipophilic molecules could accomplish that by simple diffusion mechanisms, but less lipophilic molecules or macromolecules might need to be trans- Lysates of RCCs loaded with drugs display inhibitory activities that correspond to -70% of the equivalent concentrations of free drugs. This partial reduction in biological activity might be associated with drug interaction with hemoglobin, leading to hydroxamate-induced formation of methemoglobin (Loyevsky, M., and Z. I. Cabantchik, unpublished observations), as shown in previous studies with DFO (29) . Thus at present we can not eliminate the possibility that the high hemoglobin content ofRCCs can in situ abrogate the biological activity ofthe drugs via reversible chemical interactions (i.e., reversible upon dilution). In terms ofthe mode ofentry ofthe agents into infected cells, any DFO-like drugs that enter the host cell cytosol would become virtually ineffective for parasite arrest as a result of one of the following possibilities: inaccessibility to parasites, chemical interactions with red cell components, or chemical modifications. The results of the present study are consistent with the proposed parasite membranous duct as the most feasible route for access of DFO-like chelators to parasites. Further understanding of the permeation properties of DFO derivatives into parasites and their intracellular fate in parasites and in host cells can pave the road for novel antimalarial drug design or improvement of the existing repertoire, as shown in this work.
As the antimalarial activity of all the DFO derivatives are abrogated by complexation with iron(III), it is implied that extraction of iron (III) from a parasite target mediates the cytotoxic activity. Erythrocytic parasites might not be able to efficiently restore the chelated iron and are therefore assumed to be irreversibly damaged by iron chelators of the hydroxamate families (30) .
